As part of its Post-2015 Global Tuberculosis Strategy (End TB), the World Health Organization announced new guidelines on Tuesday for the treatment of TB.
The updated guidelines call for the screening of specific vulnerable populations for latent TB infection, treating the infection to prevent the progression to active TB disease.
QIAGEN, which manufactures a new latent TB screening tool, says the company will work with international health institutions, non-governmental organizations and commercial partners to support these new guidelines.
"The World Health Organization is advancing a bold strategy for action at all stages of the disease, and we applaud the drive to eliminate this devastating epidemic,” Dr. Masae Kawamura, senior director for QIAGEN, said. “We are pleased that WHO now advocates preventive screening for latent TB infection among the most at-risk populations in addition to measures to address active disease as described in previous guideline releases."
QIAGEN's QuantiFERON-TBGold product is said to be a more accurate and quicker means to test for latent TB compared to the standard tuberculin skin test, which requires at least two patient visits and often gives false positive results.
Approximately 1.5 million people die from TB each year.